Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Diversity in clinical trials must be accompanied by justice and equity, including benefits for underrepresented participants, in order to boost population health.
Health impacts from climate change have been apparent for at least 20 years, but the climate crisis is still not treated like other global public health emergencies.
Social determinants of health can only be tackled through collaborations between public health leaders, economists, sociologists, and other non-medical stakeholders, as well as involvement from the community.
Not involving communities throughout the research process may be attributable to prejudice and a failure to recognize privilege. The result is a loss for all involved.
The reignited Cancer Moonshot must support science that will tackle health and economic impacts of cancer and promote health equity in low- and middle-income countries.
The entire biotechnology and pharmaceutical industry will be thrown into turmoil if judges can second-guess the scientific expertise of the US Food and Drug Administration.
Multilevel stakeholder engagement in policy decision-making and implementation-planning is needed to build trust and deliver evidence-based health interventions.
The Global Burden of Disease provides essential data for evidence-based healthcare, but could be improved by investment in health data systems in low- and middle-income countries
Use of AI-driven care for patients with type 1 diabetes has freed up clinicians’ time to focus on patients’ quality of life and provide more empathic, patient-centered care.